A growing body of evidence indicated that TGF-β1, CTGF, and ET-1 expressions are cooperatively augmented within the lung tissue in IPF [38, 39], supporting that TGF-β/CTGF or ET-1 axis serves as the potential target for anti-fibrotic therapy. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.